Bausch Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BAUSCH
BAUSCH has one hundred and eighty-seven approved drugs.
There are one hundred and nine US patents protecting BAUSCH drugs.
Summary for Bausch
| US Patents: | 109 |
| Tradenames: | 160 |
| Ingredients: | 125 |
| NDAs: | 187 |
| Patent Litigation for Bausch: | See patent lawsuits for Bausch |
Drugs and US Patents for Bausch
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch | JUBLIA | efinaconazole | SOLUTION;TOPICAL | 203567-001 | Jun 6, 2014 | AB | RX | Yes | Yes | 10,864,274 | ⤷ Start Trial | ⤷ Start Trial | |||
| Bausch | APLENZIN | bupropion hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 022108-002 | Apr 23, 2008 | RX | Yes | No | 7,662,407 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Bausch And Lomb | LATANOPROST | latanoprost | SOLUTION/DROPS;OPHTHALMIC | 201006-001 | Mar 22, 2011 | AT | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bausch | ATIVAN | lorazepam | TABLET;ORAL | 017794-003 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bausch | CABTREO | adapalene; benzoyl peroxide; clindamycin phosphate | GEL;TOPICAL | 216632-001 | Oct 20, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Bausch | DUOBRII | halobetasol propionate; tazarotene | LOTION;TOPICAL | 209354-001 | Apr 25, 2019 | AB | RX | Yes | Yes | 10,426,787 | ⤷ Start Trial | ⤷ Start Trial | |||
| Bausch | SYPRINE | trientine hydrochloride | CAPSULE;ORAL | 019194-001 | Nov 8, 1985 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Bausch
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bausch And Lomb Inc | TIMOPTIC-XE | timolol maleate | SOLUTION, GEL FORMING/DROPS;OPHTHALMIC | 020330-001 | Nov 4, 1993 | 4,195,085 | ⤷ Start Trial |
| Bausch | CARDIZEM LA | diltiazem hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021392-004 | Feb 6, 2003 | 6,923,984 | ⤷ Start Trial |
| Bausch Lomb Ireland | VISUDYNE | verteporfin | INJECTABLE;INJECTION | 021119-001 | Apr 12, 2000 | 6,074,666 | ⤷ Start Trial |
| Bausch | CARDIZEM CD | diltiazem hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020062-001 | Aug 10, 1992 | 5,439,689 | ⤷ Start Trial |
| Bausch | CESAMET | nabilone | CAPSULE;ORAL | 018677-001 | Dec 26, 1985 | 4,087,545 | ⤷ Start Trial |
| Bausch | CARDIZEM | diltiazem hydrochloride | TABLET;ORAL | 018602-003 | Dec 8, 1986 | 3,562,257 | ⤷ Start Trial |
| Bausch And Lomb | MIOCHOL-E | acetylcholine chloride | FOR SOLUTION;OPHTHALMIC | 020213-001 | Sep 22, 1993 | 6,261,546 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BAUSCH drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Tablets | 348 mg | ➤ Subscribe | 2009-09-24 |
| ➤ Subscribe | Cream | 3.75% | ➤ Subscribe | 2012-08-08 |
| ➤ Subscribe | Extended-release Tablets | 120 mg, 180 mg, 240 mg, 300 mg and 360 mg | ➤ Subscribe | 2005-08-30 |
| ➤ Subscribe | For Inhalation Solution | 6 gm/vial | ➤ Subscribe | 2014-05-22 |
| ➤ Subscribe | Extended-release Tablets | 65 mg and 115 mg | ➤ Subscribe | 2009-11-19 |
| ➤ Subscribe | Rectal Gel | 5 mg/mL, 4mL pre-filled syringe | ➤ Subscribe | 2008-12-08 |
| ➤ Subscribe | Extended-release Tablet | 105 rng | ➤ Subscribe | 2010-12-28 |
| ➤ Subscribe | Gel | 1.2%/2.5% | ➤ Subscribe | 2012-12-20 |
| ➤ Subscribe | Ophthalmic Solution | 0.5% | ➤ Subscribe | 2012-10-19 |
| ➤ Subscribe | Gel | 0.1% | ➤ Subscribe | 2010-07-08 |
| ➤ Subscribe | Ophthalmic Solution | 1.5% | ➤ Subscribe | 2013-09-09 |
| ➤ Subscribe | Gel | 1.2%/0.025% | ➤ Subscribe | 2010-12-17 |
| ➤ Subscribe | Gel | 0.77% | ➤ Subscribe | 2006-05-10 |
| ➤ Subscribe | Cream | 5% | ➤ Subscribe | 2006-10-17 |
| ➤ Subscribe | Extended-release Tablets | 174 mg | ➤ Subscribe | 2009-09-28 |
| ➤ Subscribe | Cream | 0.10% | ➤ Subscribe | 2008-01-31 |
| ➤ Subscribe | Extended-release Tablets | 522 mg | ➤ Subscribe | 2009-12-24 |
| ➤ Subscribe | Cream | 2.5% | ➤ Subscribe | 2014-06-17 |
| ➤ Subscribe | Extended-release Tablets | 420 mg | ➤ Subscribe | 2005-04-25 |
| ➤ Subscribe | Rectal Gel | 2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL, 15 mg/3 mL and 20 mg/4 mL | ➤ Subscribe | 2004-03-23 |
| ➤ Subscribe | Extended-release Tablet | 55 mg and 80 mg | ➤ Subscribe | 2010-12-02 |
| ➤ Subscribe | Rectal Gel | 5 mg/mL, 2mL pre-filled syringe | ➤ Subscribe | 2008-12-23 |
| ➤ Subscribe | Extended-release Tablets | 150 mg and 300 mg | ➤ Subscribe | 2004-09-21 |
| ➤ Subscribe | Gel | 1.2%/3.75% | ➤ Subscribe | 2015-09-30 |
| ➤ Subscribe | Ophthalmic Solution | 0.07% | ➤ Subscribe | 2013-07-26 |
| ➤ Subscribe | Gel | 0.04% | ➤ Subscribe | 2010-12-20 |
| ➤ Subscribe | Vaginal Gel | 0.75% | ➤ Subscribe | 2004-09-02 |
| ➤ Subscribe | Capsules | 75 mg | ➤ Subscribe | 2011-06-06 |
| ➤ Subscribe | Topical Solution | 10% | ➤ Subscribe | 2018-06-06 |
| ➤ Subscribe | Lotion | 0.1% | ➤ Subscribe | 2016-08-31 |
International Patents for Bausch Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Norway | 20080444 | ⤷ Start Trial |
| Ecuador | SP109923 | ⤷ Start Trial |
| Japan | 2015027983 | ⤷ Start Trial |
| Spain | 2720149 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2009128932 | ⤷ Start Trial |
| Russian Federation | 2018121523 | ⤷ Start Trial |
| Canada | 3063371 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Bausch Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2233112 | 132014902285293 | Italy | ⤷ Start Trial | PRODUCT NAME: FLUOCINOLONE ACETONIDE(ILUVIEN); AUTHORISATION NUMBER(S) AND DATE(S): 042616019, 20140530;PL27813/0001, 20120504 |
| 2826776 | CA 2021 00013 | Denmark | ⤷ Start Trial | PRODUCT NAME: A COMBINATION OF (A) (R)-1-(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANECARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND (B) ....; REG. NO/DATE: EU/1/18/1306 20181106 |
| 3265085 | CA 2026 00031 | Denmark | ⤷ Start Trial | PRODUCT NAME: DEUTETRABENAZINE; REG. NO/DATE: EU/1/25/1956 20260109 |
| 0617614 | 2001/009 | Ireland | ⤷ Start Trial | PRODUCT NAME: PANRETIN-ALITRETINOIN |
| 2316456 | LUC00054 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE; AUTHORISATION NUMBER AND DATE: EU/1/14/988 20150330 |
| 0237929 | 68/1997 | Austria | ⤷ Start Trial | PRODUCT NAME: TOLCAPONE; REGISTRATION NO/DATE: EU/1/97/044/001 - EU/1/97/044/006 19970827 |
| 0427680 | SPC/GB03/015 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: PIMECROLIMUS OR SALTS OR ESTERS THEREOF; REGISTERED: DK 21034 (MT-NO.32700) 20020315; UK PL 00101/0659 20021003 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
